Development pipeline

CMV-Gyn (Cytotect 70) - BT-084

CMV-Gyn (Cytotect 70) is a polyclonal immunoglobulin produced from human plasma, which contains large amounts of antibodies against human cytomegaloviruses (CMV).

Primary CMV infection is the most common infection that can be transmitted from a pregnant woman to the foetus and lead to permanent injuries in the foetus.

In up to 25% of infected children, the infection can lead to serious medical complications such as deafness and neurological abnormalities and even death. A clinical phase III trial is examining whether administration of CMV-Gyn to pregnant women who become infected with CMV for the first time during pregnancy can reduce transmission of the virus to the foetus and also reduce the complications of an infection.

Clinical trials

Title

Indication

Status

 
Cytotect 70 (Study 963) Congenital CMV infection prophylaxis Recruitment completed

Congenital CMV infection prophylaxis

Link clinicaltrialsregister.eu